Targeting PI3K/Akt/mTOR Signaling in Cancer

Area of Science:

• Cell Biology
• Biochemistry
• Oncology

Background:

• The PI3K/Akt and mTOR pathways are critical regulators of cell growth, proliferation, survival, and metabolism.
• These pathways are frequently dysregulated in various cancers, making them attractive therapeutic targets.
• The interconnectedness of PI3K/Akt and mTOR suggests a unified signaling network.

Purpose of the Study:

• To provide an overview of the biological significance and components of the PI3K/Akt and mTOR pathways.
• To review the current landscape of PI3K, Akt, and mTOR inhibitors in development.
• To highlight the progression of these inhibitors from preclinical research to clinical application.

Main Methods:

• Literature review of the PI3K/Akt and mTOR signaling pathways.
• Analysis of the development status of specific inhibitors targeting PI3K, Akt, and mTOR.
• Compilation of information on registered medicines and novel compounds.

Main Results:

• Detailed overview of the PI3K/Akt and mTOR pathway components and their biological roles.
• Comprehensive summary of existing and emerging PI3K, Akt, and mTOR inhibitors.
• Categorization of inhibitors based on their stage of development, from bench to bedside.

Conclusions:

• The PI3K/Akt and mTOR pathways represent a crucial signaling axis in cellular physiology and pathology, especially cancer.
• Targeting these pathways with specific inhibitors offers significant therapeutic potential.
• Ongoing development of novel inhibitors promises new treatment strategies for cancer and other diseases.